{
  "retracted": false,
  "timestamp": 1556582400000,
  "updates": [
    {
      "timestamp": 1588117248196,
      "identifier": {
        "doi": "10.1007/s40264-019-00830-5"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s40264-019-00812-7"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists"
}
